Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 6Recurrence 3Mastocytosis, Systemic 2Leukemia, Mast-Cell 2Sarcoma 1Neoplasms 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Recurrence × avapritinib × Clear all
NCT04773782 2026-01-13

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Blueprint Medicines Corporation

Phase 1/2 Completed
29 enrolled
CNS

Glioma, Recurrence, Central Nervous System Neoplasms

NCT04908176 2024-12-13

A Drug-drug Interaction Study of Avapritinib and Midazolam

Blueprint Medicines Corporation

Phase 1 Completed
10 enrolled
CNSGastrointestinalSarcoma

Glioblastoma, Neoplasms, Recurrence, Gastrointestinal Stromal Tumors

NCT02561988 2023-03-17

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Blueprint Medicines Corporation

Phase 1 Completed
86 enrolled 1 FDA
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Recurrence, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡